DiaMedica Therapeutics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate
Portfolio Pulse from Benzinga Newsdesk
DiaMedica Therapeutics reported Q1 2024 GAAP EPS of $(0.14), surpassing the $(0.16) estimate and marking a 30% improvement over last year's $(0.20) per share loss.
May 08, 2024 | 10:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DiaMedica Therapeutics reported a smaller-than-expected loss per share of $(0.14) for Q1 2024, beating estimates and showing significant improvement from the previous year.
Beating EPS estimates and showing year-over-year improvement is generally viewed positively by the market, suggesting potential short-term upward price movement for DMAC.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100